Roche Full-Year Report 2022

• Group sales grow by 2% at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisions
• Pharmaceuticals Division sales increase by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)
• Diagnostics Division sales grow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the year

Highlights in the fourth quarter of 2022 (incl. January 2023):

• US approvals of Lunsumio (follicular lymphoma), Tecentriq (advanced rare sarcoma) and Actemra/RoActemra (COVID-19)
• US priority review of glofitamab (aggressive form of blood cancer)
• Positive phase III data for Vabysmo (serious retinal vascular condition) and for Tecentriq plus Avastin (early-stage liver cancer)
• Priority review for crovalimab (rare blood disease) in China
• New study proves high medical value of Elecsys NT-proBNP heart test
• US approval for Alzheimer’s tests; US Emergency Use Authorization for mpox virus test